Porvair acquires J.G. Finneran Associates
Finneran bringing glass, plastics and assembly manufacturing capabilities and strong US distribution.
Porvair Sciences is pleased to welcome J.G. Finneran Associates into the Porvair family following its acquisition by Porvair plc.
Based in Vineland, New Jersey, J.G. Finneran designs, manufactures and distributes specialist laboratory consumables including vials, filters, microplates, closures and ancillary products. Finneran products clearly complement the biotechnology and chromatography product lines of Porvair Sciences and the combined product ranges will provide an enhanced offering to all customers.
There is a good fit and synergy between the J.G. Finneran and Porvair Sciences businesses with Finneran bringing glass, plastics and assembly manufacturing capabilities as well as strong US distribution. This complements the strong UK-based manufacturing and distribution capabilities of Porvair Sciences and together the businesses have a broad product offering for chromatography, sample preparation and environmental laboratories.
Both companies have a strong history of innovation and this will continue with emphasis on developing unique solutions for sample preparation in biotechnology and chromatography applications based around their core vial, microplate and filtration capabilities. Customers will benefit from Porvair Sciences products being manufactured, stocked and distributed from J.G. Finneran’s facility in Vineland USA, as well as Finneran products being distributed from Wrexham UK. This is an exciting time in the development of both companies who look forward to achieving significant growth in the international scientific laboratory marketplace.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.